Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 6, 1996, Pages 593-600

  Gosland, Michael P ^a   Gillespie, Mark N ^b   Tsuboi, Clifford P ^a   Tofiq, Sharmen ^a   Olson, Jack W ^a   Crooks, Peter A ^a   Aziz, Shewan M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Difluoromethylornithine (DFMO); Multidrug resistance; Polyamines

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; DOXORUBICIN; DRUG CONJUGATE; EFLORNITHINE; ETOPOSIDE; GENE PRODUCT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE REVERSAL AGENT; PACLITAXEL; POLYAMINE; POLYMER; PUTRESCINE; RADIOISOTOPE; SPERMINE; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINBLASTINE SULFATE;

AMINE TRANSPORT; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG UPTAKE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SARCOMA CELL;

ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; GUANIDINES; HUMANS; PACLITAXEL; POLYMERS; SARCOMA; SPERMINE; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0029944732     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050434     Document Type: Article

References (40)

1. Pegg AE (1986) Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 234:249
2. Janne J, Alhonen L, Leinonen P (1991) Polyamines: molecular biology to clinical applications. Ann Med 23:241
3. Pegg A (1988) Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 48:759
4. Janne J, Poso H, Raina A (1978) Polyamines in rapid growth and cancer. Biochim Biophys Acta 473:241
5. Moulinoux JP, Quemener V, Khan NA (1991) Biological significance of circulating polyamines in oncology. Cell Mol Biol 37:773
6. Seiler N, Sarahan S, Grauffel C, Jones R, Knodgen B, Moulinoux J (1990) Endogenous and exogenous polyamines in support of tumor growth. Cancer Res 50:5077
7. Quemener V, Blanchard Y, Chamaillard L, Havouis R, Cipolla B, Moulinoux J (1994) Polyamine deprivation: a new tool in cancer treatment. Anticancer Res 14:443
8. Edwards ML, Prakaish NJ, Stemerick DM, Sunkara SP, Bitonli AJ, Davis GF, Dumont JA, Bey P (1990) Polyamine analogues with antitumor activity. J Med Chem 33:1369
9. Regenass U, Caravatti G, Mett H, Stanek J, Schneider P, Muller M, Matter A, Vertino P, Porter CW (1992) New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity. Cancer Res 52:4712
10. Creaven PJ, Pendyala L, Petrelli NJ (1993) Evaluation of α-difluromethylornithine as a chemopreventive agent: tolerance to daily oral administration in humans. Cancer Epidemiol Biomarkers Prev 2:243
11. Love R, Carbone P, Verma A, Gilmore D, Carey P, Tutsch K, Pomplen M, Wilding GA (1993) A randomized phase I chemoprevention dose-seeking of α-difluromethylornithine. J Natl Cancer Inst 85:732
12. Porter CW, Janne J (1987) Modulation of antineoplastic drug action by inhibitors of polyamine biosynthesis. In: McCann PP, Pegg AE, Sjoerdsma A (eds) Inhibition of polyamine metabolism: biological significance and basis for new therapies. Academic Press, New York, p 203
13. Abeloff MD, Rosen ST, Luk GD, Baylin SB, Zeltman M, Sjoerdsma A (1986) Phase II trials of alpha-difluromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat Rep 70:843
14. Cornbleet MA, Kingsworth A, Tell GP, Haegele KD, Joder-Ohlenbusch AM (1989) Phase I study of methylacetylenic putrescine, an inhibitor of polyamine synthesis. Cancer Chemother Pharmacol 23:348
15. Haven CA, Olson JW, Arcot SS, Gillespie MN (1992) Polyamine transport and ornithine decarboxylase activity in hypoxic pulmonary smooth muscle cells. Am J Resp Cell Mol Biol 7: 286
16. Mitchell JA, Diveley RR, Mitchell JL (1992) Abnormal accumulation and toxicity of polyamines in a difluromethylornithine-resistant HTC cell variant. Biochim Biophys Acta 1136:136
17. Seiler N, Dezeure F (1990) Polyamine transport in mammalian cells. Int J Biochem 22:211
18. Lum B, Gosland M, Kaubisch S, Sikic B (1993) Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 13:88
19. Simon S, Schindler M (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91:3497
20. Gottesman MM (1993) How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 53:747
21. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155
22. Biedler J (1994) Drug resistance: genotype and phenotype: thirty-second G.H.A. Clowes Memorial Award lecture. Cancer Res 54:666
23. Aziz SM, Gosland MP, Crooks PA, Olson JW, Gillespie MN (1995) A novel polymeric spermine conjugate inhibits polyamine transport in pulmonary smooth muscle cells. J Pharmacol Exp Ther 274:181
24. Aziz SM, Gosland MP, Tofiq SF, Tsuboi CP, Olson JW, Gillespie MN (1994) Polyamine transport inhibitors as antineoplastic agents. Proc Am Assoc Cancer Res 35:349
25. Gosland M, Tsuboi C, Hoffman T, Goodin S, Vore M (1993) 17β-Estradiol glucuronide: an inducer of cholestasis and a physiological substrate for multidrug resistance transporter. Cancer Res 53:5382
26. Mosman T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55
27. Gosland MP, Lum BL, Sikic BI (1989) Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastinein multidrug resistant human sarcoma cells. Cancer Res 49:6901
28. Harker WG, Sikic BI (1985) Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45:4091
29. Toursarkissian B, Endean ED, Aziz SM (1994) Characterization of polyamine transport in rat aortic smooth muscle cells. J Surg Res 57:401
30. Aziz SM, Olson JW, Gillespie MN (1994) Multiple polyamine transport pathways in cultured pulmonary artery smooth muscle cells: regulation in hypoxia. Am J Resp Cell Mol Biol 10:160
31. Khan N, Fardel O, Havouis R, Fauchet R, Moulinoux JP (1994) Transport and metabolism of polyamines in wild and multidrug resistant human leukemia (K 562) cells. Leuk Res 18:283
32. 11-diethylnorspermine. Cancer Res 54:5917
33. Regenass U, Mett H, Stanek J, Schneider P, Muller M, Matter A, Vertino P, Porter CW (1994) CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum anti-proliferative and antitumor activity. Cancer Res 54:3210
34. Zhi-Min Y, Egorin M, Rosen M, Simon M, Callery P (1994) Cellular pharmacology of N1- and N8-aziridinyl analogues of spermidine. Cancer Res 54:742
35. 12-bis(ethyl)spermine. Cancer Res 53:2071
36. Kramer DL, Miller JT, Khomutov R, Khomutov A, Bergeron RJ, Porter CW (1993) Regulation of polyamine transport by polyamines and polyamine analogs. J Cell Physiol 115:399
37. Zamora J, Pearce H, Beck W (1988) Physical-chemical properties of compounds that modulate multidrug resistance in human leukemia cells. Mol Pharmacol 33:454
38. Breuer W, Slotki IN, Ausiello DA, Cabantchick IZ (1993) Induction of multidrug resistance down-regulates the expression of CFTR in colonie epithelial cells. Am J Physiol 265:C1711
39. Hyde SC, Emsley P, Hartshorn M, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard R, Higgins CF (1990) Structural model of ATP-binding proteins associated with cystic fibrosis. Multidrug resistance, and bacterial transport. Nature 346:362
40. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI (1993) Clinical trials of modulation of multidrug resistance: pharmacokinetic and pharmacodynamic considerations. Cancer 72 (Suppl 11):3502